Secretagogue Peptide
EGRIFTA
TH9507
A 44-amino acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical research. Premium Research Peptide.
Third Party Tested by Freedom Diagnostics
Peer-reviewed research
Journal of Clinical Endocrinology & Metabolism
Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fa...
2010
PMID: 20554713
Falutz J, et al.
Lancet HIV
Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind,...
2019
PMID: 31611038
Stanley TL, et al.
Archives of Neurology
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive...
2012
PMID: 22869065
Baker LD, et al.
Journal of Clinical Endocrinology & Metabolism
The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases...
2019
PMID: 31050749
Adrian S, et al.
JCI Insight
Effects of tesamorlin on hepatic transcriptomic signatures in HIV-associated NAFLD
2020
PMID: 32780726
Fourman LT, et al.
FDA
EGRIFTA (tesamorlin) Prescribing Information
2025
Theratechnologies Inc.
